Castle Biosciences股价因Medicare拒绝承保而下跌
Investing.com -- Castle Biosciences (NASDAQ:CSTL)股价下跌9%，此前地区Medicare承包商Novitas最终决定不承保该公司的一项癌症检测。Novitas Medicare行政承包商 (MAC)确认了一项地方承保决定 (LCD)，导致不承保Castle的DecisionDx-SCC检测。这一决定将于2月23日生效。
US proposes payment rate for 2026 Medicare Advantage insurers
The U.S. government on Friday proposed 2026 reimbursement rates for Medicare Advantage plans run by private insurers that ...
Medicare and telehealth: more restrictive rules could hit patients in 2025
Congress recently pulled a similar stunt on Medicare beneficiaries. But in this case, the result was more than just ...
STAT4 小时
Biden’s final Medicare Advantage regulation would hike payments to insurers
The Biden administration’s final regulation affecting the Medicare Advantage industry would come with a much lighter touch ...
News Medical7 分钟
Pharmacy benefit managers steer Medicare patients to use their own pharmacies
Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their ...
Raw Story on MSN3 小时
Leaked GOP list outlines plan to cut $479B from Medicare: Politico
Politico has acquired an early list from Republican lawmakers that shows the programs they're considering slashing from the ...
Medicare caps seniors drug expenses: What you need to know
Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.
Center on Budget and Policy Priorities11 小时
Growth in Medicare Advantage Raises Concerns
MA plans are substantially overpaid compared to traditional Medicare. Much of these overpayments benefit the MA plans rather ...
Ozempic, Trulicity among Medicare's priciest drugs, report finds
Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...
KSTP-TV2 小时
Change in Medicare prescription drug coverage will help millions
There’s a major change in 2025 to Medicare’s prescription drug coverage. This year, there’s a new $2,000 cap on annual out-of ...
Medicare扩大肾移植检测覆盖范围
加利福尼亚州尔湾 - 市值目前为3800万美元的分子诊断公司Oncocyte Corp. (NASDAQ: OCX)宣布,其VitaGraft Kidney肾移植患者检测获得了Medicare扩大覆盖范围。这一决定源于一项研究表明该检测在早期发现移植排斥反应方面的有效性。根据 InvestingPro 的数据,尽管公司面临重大运营挑战,但其股票目前的交易价格接近其公允价值。分子诊断计划 ...
Here We Go Again: The Medicare Advantage Open Enrollment Period
The Medicare Advantage Open Enrollment Period (Jan 1–Mar 31) lets you switch plans or adjust coverage. Review your options to ...